Rosuvastatin Counteracts Vessel Arterialisation and Sinusoid Capillarisation, Reduces Tumour Growth, and Prolongs Survival in Murine Hepatocellular Carcinoma
Figure 2
Rosuvastatin prevents sinusoid abnormalisation in HCC livers. (a) Representative images of haematoxylin-eosin (HE) staining in normal liver (N) and untreated and rosuvastatin-treated HCC livers (/group) at 16 weeks. Sinusoids are indicated by white arrowheads. Thin and regular sinusoids were observed in normal livers, whilst enlarged, tortuous, and fused sinusoids were present in untreated HCC livers. These sinusoidal anomalies were more marked within the nodular regions in untreated HCC livers. In rosuvastatin-treated HCC livers, these sinusoidal anomalies were less marked than those in untreated HCC livers. (b) Representative images of CD31 immunostaining in normal livers (N, ) and in untreated and rosuvastatin-treated HCC livers (/group) at 16 weeks. CD31-stained endothelial cells lining vessels derived from the portal tract (VDPT) (white arrow) and endothelial cells lining the sinusoids (white arrowhead). (c) Quantification of the CD31-positive sinusoid surface area per field in untreated HCC () and in rosuvastatin-treated HCC liver () at 16 weeks. Data are mean ± SEM, .
